抗体偶联药物在胃癌治疗中的研究与思考  

Recent advances in antibody-drug conjugates for the treatment of gastric cancer

作　　者：肖礼海 夏钢 王坚成[1] Xiao Lihai;Xia Gang;Wang Jiancheng(School of Pharmaceutical Sciences,Peking University,Beijing 100191,China;Zhejiang Medicine Co.,Ltd.Xinchang Pharmaceutical Factory,Shaoxing 312500,Zhejiang,China;Zhejiang NovoCodex Biopharmaceuticals Co.Ltd.,Shaoxing 312366,Zhejiang,China)

机构地区：[1]北京大学药学院,北京100191 [2]浙江医药股份有限公司新昌制药厂,浙江绍兴312500 [3]浙江新码生物医药有限公司,浙江绍兴312366

出　　处：《生物医学转化》2022年第1期20-31,共12页Biomedical transformation

摘　　要：抗体偶联药物(Antibody-Drug Conjugates,ADCs)是一类新型的肿瘤靶向治疗药物,一般由单克隆抗体和细胞毒药物通过连接子偶联而成,同时具有抗体药物高选择性和化疗药物高活性的优势。经过几十年的临床前和临床研究,目前已有多个抗体偶联药物在临床上被广泛用于治疗多种类型的肿瘤。本文就应用于胃癌治疗的抗体偶联药物的研究进展进行综述。Antibody-drug conjugates(ADCs),generally consisting of cytotoxic agents conjugated to monoclonal antibodies via linkers,are a new class of targeted antitumor therapeutics that combine the advantages of high specificity of antibody and high cytotoxicity of chemotherapy drugs.After decades of preclinical and clinical research,a group of ADCs have been widely used for treatments of many types of tumors.This review summarizes recent advances in ADCs for the treatment of gastric cancer.

关 键 词：抗体偶联药物 胃癌 研究进展 

分 类 号：R730.5[医药卫生—肿瘤] R735.2[医药卫生—临床医学]